Therefore, targeting macrophage-intrinsic innate immune activation by either blocking macrophage-specific receptors which can mediate SARS-CoV-2 uptake, or through administration of RIG-I/MDA-5 antagonists present a novel therapeutic strategy for combating hyperinflammation in COVID-19 patients. The gene discussed is RIGI; the disease is COVID-19.